Scientific Fulminant Multiple Sclerosis


Well-known member
In countering the USPO's Examiner's rejection of Thomas Luger's patent application for treatment of multiple sclerosis with a-msh, Luger's team has put forward a new amendment using a mouse model based on Devic's disease (neuromyelitis optica) claiming it is a form of multiple sclerosis and should provide enough evidence that the method works as stated. The USPO Examiner has been forthright in both this application and Clinuvel's abandoned CNS/MS application that what is being proposed is not demonstrative of possession of the method, so I'd be surprised if this new amendment gets approved. But not to take away from Luger, he is exceptionally persistent and has fought all claims to their ends and in some cases won.

Another curious detail Luger's team pointed out is they say this treatment will only ameliorate MS symptoms not cure it, and that the Examiner should approach the matter accordingly. They aren't claiming a cure just amelioration, which is backed up by their new supporting evidence from the Devic's disease model.

Another aspect of the Examiner's argument which I found silly was their problem with the broad application regarding dosage and delivery method, basically saying it wasn't specific enough. Luger's team has responded that it is totally within the scope of the skilled person to determine the dosage form, referencing Scenesse as an example. If I recall correctly, Clinuvel has stated in one their earlier AIS PRs that the correct dosage form is yet to confirmed (Phase 2b?). Yes, they said they have four dosage forms worked out already (Prenumbra?) but these still need to be clinically confirmed. I'm not sure in this instance the Examiner's argument can stand up to scrutiny.

As an aside, if Clinuvel is waiting on the outcome of Luger's patent application, it will be some time before the 6th indication is announced if MS is indeed what it is. Probably not till 2022 at the earliest (speculation).
Last edited:


Well-known member
Nothing related to fulminant MS specifically, but I think it's the best fit among all threads.

Acthar seems to simulate the melanocortin system quite well and is FDA approved for multiple indications. Despite all the legal/fraud issues, annual sales of Acthar is still approx. 800 MUSD. Huge potential ahead for a safer, more effective treatment if available. I don't know the receptor binding ability of Acthar vs Afamelanotide though.

"FDA has repeatedly affirmed Acthar’s beneficial effects". So they should come to the same conclusion with afamelanotide, right?

CUV Quote (Yesterday's close)

Time: 4:10PM AEDT
Price: 39.19
Volume: 69444